Mr. Guy LaTorre reports

BREATHTEC BIOMEDICAL ANNOUNCES PLANS FOR BREATH ANALYSIS CLINICAL TRIALS AT CANADIAN TECH FACILITY

Breathtec BioMedical Inc. is holding a press conference today to provide plans for the commencement of the company's clinical trial program at Innovation Boulevard located in Surrey, B.C.

Today's announcement marks the beginning of an intensive research review into NA-Nose, an advanced-stage, nanotechnology-based breath-analysis device from the Technion -- Israel Institute of Technology -- which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen British Columbia and Surrey to hold its clinical trials for selected respiratory infections at the health and technology district on Innovation Boulevard.

"Breathtec's exciting technology, developed in Israel, is going through the highest-quality clinic trials right here in British Columbia," said Minister of Technology, Innovation and Citizens' Services, Amrik Virk. "We have a vibrant tech sector attracting companies from clean tech, to information and communications systems, to life sciences -- this kind of innovative work is a key part of our diversified economy."

"The City of Surrey supports the development of health technologies and we welcome Breathtec Biomedical to our growing stable of health technology specialist firms," said Mayor Linda Hepner. "The addition of Breathtec is another example of how the City of Surrey is committed to working together to help take innovative science and technology ideas off the drawing board and turning them into real working solutions that will improve the quality of life for all."

Breathtec chief executive officer Guy LaTorre stated: "We are delighted to come to the city of Surrey, B.C., and to have the opportunity to access such a world-class facility and team. The NA-Nose device is an exciting new late-stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company's focus."

During the event, NA-Nose lead researcher Dr. Hossam Haick will demonstrate how the nanotechnology-based breath-analysis system is used for screening of potentially life-threatening diseases. The licensed technology will be clinically evaluated as a non-invasive point-of-care device for early detection of community- and hospital-based infections such as streptococcus; methicillin resistant (MRSA); staphylococcus; enterococcus; vancomycin resistant (VRE); pneumococcus; hemophilus influenza (HiB); chicken pox; and the common cold.

Press conference -- Tuesday, June 28, at 11 a.m. Pacific Daylight Time, 2 p.m. Eastern Daylight Time

Where:  City Centre 1, 13737 96th Ave., HealthTech Innovation Hub (second floor), Surrey, Canada

In attendance

• Mr. Virk, Minister of Technology, Innovation and Citizens' Services;
• Ms. Hepner, mayor of Surrey;
• Mr. LaTorre, chief executive officer, Breathtec Biomedical;
• Dr. Haick, professor in chemical engineering and nanotechnology at Technion -- Israel Institute of Technology (product demonstrations);
• Dr. Raj Attariwala, MD, PhD, lead engineer, Breathtec Biomedical.

Innovation Boulevard is an agile partnership of health, business, higher education and government coming together and creating new health technologies to improve peoples' lives through a shared vision to achieve innovative results, improve health outcomes for patients, implement intelligent solutions for the health care economy, attract talented clinicians and researchers, and to grow companies in the health care technology and services sector.

We seek Safe Harbor.